Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc.

LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Prime Medicine, Inc. today and set a price target of $6.00. According to Ti...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRME	$3.08	+4.41%	1.98M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRME	$3.08	+4.4%	1.98M
3
4
5
6

PRME

PRME

Get Prime Medicine, Inc. Data in Excel

Get Prime Medicine, Inc. Data in Excel